****Published July 2019****

MarketVIEW: Respiratory Syncytial Virus (RSV) monoclonals
(CAT: VAMV023B)

Product Name	:	**MarketVIEW:** Respiratory Syncytial Virus (RSV) monoclonals
Description	:	Global commercial opportunity assessment [52 countries]
Contents	:	Executive presentation (~80 slides.pdf) + 2 x MS-Excel forecast model(s) (.xls)
Therapeutic Area	:	**Novel monoclonal antibodies: infant**
Publication date	:	July 2019
Catalogue No	:	VAMV023B

Background

Human **respiratory syncytial virus (RSV)** is one of the most common viruses to infect children worldwide and now increasingly is recognized as an important pathogen in adults, especially the elderly. Globally each year, there are over **33m** episodes of RSV-associated acute lower respiratory infection in children younger than 5 yrs of age resulting at least **3.2m** hospital admissions and **59,600** in hospital deaths (2015 estimation, Shi T *et al*., 2017). In children below 5 yrs, the burden of RSV exceeds that of influenza and other respiratory viral pathogens. There is no specific treatment for RSV infection and for those children who require hospitalization (~1-2% of healthy), supportive therapy is still the mainstay of care. **Palivizumab** (anti-RSV monoclonal, **Synagis®**) has been FDA approved since 1998 for the prophylaxis of specific subsets of premature infants.

Newer long-acting monoclonal antibodies such as **MEDI8897** (Nirsevimab, MedImmune) and **MK-1654** (Merck & Co) are currently in development with promising data. A key question is whether these interventions can obviate the need for prophylatic active vaccines.

This **MarketVIEW** product is an Executive Presentation (~80 slides) and 2 x MS-Excel forecast models (> 60 worksheets) which investigate the two deployment scenarios and the commercial potential of newer long-acting monoclonal antibodies in all relevant birth types to 2035. **52 countries**[1] and **sub-regions** are included in the model with expected public and private sector use being indicated. A methodology has been created whereby country specific roll-out is forecasted according to specific local factors and RSV transmission patterns which may influence RSV mAb adoption timing. The report contains a detailed palivizumab (Synagis) case study, review of the R&D competitive environment for new mAbs and expected pricing strategies according to their deployment regime. Discussion/modelling of the interplay between mAbs and RSV vaccines has been added. This product is ideally suited to organisations wishing to access an up-to-date global quantification of the monoclonal opportunity. **It is designed to be complementary to the sister product focused on RSV vaccines (CAT no: VAMV023).**

[1] US, Canada, Australia, M5EU + Other EU1 and 2, Brazil, Argentina, Chile, Other PAHO, South Korea, Japan, Other International, India, China, Russia

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44(0)1279 927049 e-mail: info@vaczine-analytics.com

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to RSV monoclonals in each respective market. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of respiratory based-pathogens, especially Pertussis (Tdap) and Influenza has also been utilised. Palivizumab [Synagis] has been used as a case study.

PRODUCT CONTENTS:

Published July 2019 (CAT No: VAMV023B)

****This product is a summary presentation (.pdf), a forecast model (.xls)

Contents – Summary presentation (.pdf)[2]

PAGES: ~80 slides fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand models x 2 (MS Excel-based)

Worksheets = >60 interconnected

[2] Full contents i.e. title per slide is proprietary and only available upon valid request

PRODUCT COST:
VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT (both deliverables) - USD **$8,995.00**/ GBP **£7,200.00#** (Region license)*

*A region is North America, Europe or ROW
For orders in the UK, VAT at 20% will be added to the final invoice total
 # - indicative prevailing rate will be applied on date of transaction, third-party licenses may be restricted/vary

HOW TO ORDER:
To order, please contact your region account manager or order direct at orders@vaczine-analytics.com This report can also be purchased online. Please review the **TERMS and CONDITIONS** of purchase.

BIBLIOGRAPHY

~73 References – only available upon valid request

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44(0)1279 927049 e-mail: info@vaczine-analytics.com

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as "The Company"). (Herein [enter client name] to as "The Client").

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (a division of Assay Advantage Ltd).
2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.
3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.
4. If not purchased online invoices are payable within **thirty days** of the invoice date.
5. All proposals are quoted in **$USD dollars or £GBP or €euro** and invoices are to be settled in the same currency.
6. The Company agrees not to disclose to any third-party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees, and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics
A division of Assay Advantage Ltd
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 927049 / Fax: +44 (0) 1279 927049
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new monoclonals and biologics.

For more information, please visit our website www.vacZine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44(0)1279 927049 e-mail: info@vaczine-analytics.com